The patient biotech giant came to prominence by developing treatments for rare genetic disorders, a process usually fraught with risk and expense. But in January, the company announced that it expects its 20% compound annual earnings growth to continue through 2011.
Genzyme has recently added renal, bone, and cancer treatments. A 10-year study by the American Academy of Orthopaedic Surgeons just reported good news for the company's Carticel, a cell therapy that uses a patient's own cartilage to repair damaged knees. Says Dr. Lyle Cain Jr., an orthopedic surgeon in Birmingham, Alabama: "This is the beginning of the next generation of procedures."
Recent Comments | Total
October 17, 2009 at 10:09am by Gabbos Gabbs
share search
October 17, 2009 at 10:44am by Gabbos Gabbs
fileshare
November 4, 2009 at 6:16am by andrew zverev
megaupload search
November 4, 2009 at 6:41am by andrew zverev
megaupload search